Cisplatin triggers platelet activation.
Clinical observations suggest that anticancer drugs could contribute to the thrombotic complications of malignancy in treated patients. Thrombotic microangiopathy, myocardial infarction, and cerebrovascular thrombotic events have been reported for cisplatin, a drug widely used in the treatment of many solid tumours. The aim of this study is to explore in vitro cisplatin effect on human platelet reactivity in order to define the potentially active role of platelets in the pathogenesis of cisplatin-induced thrombotic complications. Our results demonstrate that cisplatin increases human platelet reactivity (onset of platelet aggregation wave and thromboxane production) to non-aggregating concentrations of the agonists involving arachidonic acid metabolism. Direct or indirect activation of platelet phospholipase A(2) appears to be implicated. This finding contributes to a better understanding of the pathogenesis of thrombotic complications occurring during cisplatin-based chemotherapy.
Togna
G I
GI
Department of Human Physiology and Pharmacology, University of Rome "La Sapienza," Italy. tognagi@uniroma1.it
Togna
A R
AR
Franconi
M
M
Caprino
L
L
D000970:Antineoplastic Agents / Q000494:pharmacology; D016718:Arachidonic Acid / Q000378:metabolism / Q000494:pharmacology; D002945:Cisplatin / Q000009:adverse effects / Q000494:pharmacology*; D003094:Collagen / Q000494:pharmacology; D006801:Humans; D008297:Male; D015539:Platelet Activation / Q000187:drug effects*; D013929:Thromboxane B2 / Q000096:biosynthesis; D014316:Tritium
D000970:Antineoplastic Agents; D014316:Tritium; D016718:Arachidonic Acid; D013929:Thromboxane B2; D003094:Collagen; D002945:Cisplatin